在患有1组肺高血压的患者中,上心室动脉动脉切除后的结果
Tejus Satish1, Kelly Chin1, Nimesh Patel1
1University of Texas Southwestern Medical Center, Dallas, TX 75390-9030, USA.
对于肺高血压 (PH) 中的脑膜上性心跳动 (SVTs) 进行导管切除是可行的,但存在风险. 成功率因SVT类型而异,心房动和非典型心房动的复发率较高.
科学领域:
- 心脏病学 心脏病学
- 电力生理学 电力生理学
- 肺高血压研究 肺高血压研究
背景情况:
- 肺高血压 (PH) 导致右心室应变和心房变化,增加了脑上高心率 (SVT) 的风险.
- 世界卫生组织 (世卫组织) 1组PH患者的导管SVT切除结果尚未确定.
研究的目的:
- 评估导管SVT切除在WHO1组PH患者中的安全性和有效性.
- 在消去后的3个月和1年内描述程序成功率和复发率.
主要方法:
- 在10年内对WHO组1PH患者进行了导管SVT切除的回顾性队列研究.
- 从电子医疗记录中提取的数据,包括基线特征和程序结果.
主要成果:
- 在38名患者中,60个SVT的切除显示出可变的初始成功率 (例如,典型心房的89.7%,非典型心房的57.1%).
- 一年复发率高于心房动 (100%) 和非典型心房 flutter (50%),但低于典型心房 flutter (25%) 和心房低心率 (28.6%).
- 术前并发症发生在18.4%的患者中,其中有一例死亡 (2.6%).
结论:
- 在1组PH中进行SVT切除是相对安全和有效的,尽管其成功率较低,并且脱补偿的风险比一般人群更高.
- 与普通人群相比,心房动和非典型心房的复发率更高.
更多相关视频
10:46Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Dysrhythmias II: Classification of Tachyarrhythmias
Aortic Regurgitation III: Medical Management
